Published in Hospital Business Week, February 4th, 2007
The RSV clinical material will be used by a contract biopharmaceutical client to conduct human challenge studies in order to establish optimal infectious levels in healthy adult volunteers. The client, Alnylam Pharmaceuticals, has commenced a clinical program to evaluate the anti-viral activity of its therapeutic product for treatment of RSV...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week